Abstract ND06: ABBV-CLS-484: An active site PTPN2/N1 inhibitor that augments the immune response and sensitizes tumors to immune-mediated killingChristina K. Baumgartner, Philip R. Kym, Marcia N. Paddock et al.|Cancer Research|2022Cited by 7